Enabling Development of Paediatric Medicines in Europe: 10 Years of the EU Paediatric Regulation

  • Paolo A. Tomasi
  • Gunter F. Egger
  • Chrissi Pallidis
  • Agnes Saint-Raymond
Current Opinion
  • 1 Downloads

Abstract

The year 2017 marks the tenth anniversary of entry into force of the Paediatric Regulation in the European Union (EU). This law aimed to stimulate the development of paediatric medicines and provide more information on their use, as a response to the lack of evidence and approval of medicines for children. The European Medicines Agency (EMA) has had a central role in the implementation of the Regulation. Pharmaceutical companies need to submit a paediatric investigation plan (PIP) to the EMA’s Paediatric Committee (PDCO) for every new medicine, unless an exemption (waiver) is granted. The plans, which describe the development of drugs for children, must be agreed well in advance of the request for marketing authorization of the medicine. Deferrals of studies can be granted to allow approval in adults before the completion of paediatric studies. Between January 2007 and December 2016, a total of 273 new medicines and 43 additional pharmaceutical forms appropriate for use in children were authorized in the EU, and 950 PIPs were agreed by the EMA. In addition, 486 waivers of the development of a medicine in one or more medical conditions were agreed. The Paediatric Regulation has had a very positive impact on paediatric drug development, as exemplified by a comparison of two periods of 3 years before and after entry into force of the Regulation. We conclude that the Regulation has resulted in more medicines for children and more information on the pediatric use of medicines in the EU being available to clinicians.

References

  1. 1.
    Bourgeois FT, Murthy S, Pinto C, Olson KL, Ioannidis JPA, Mandl KD. Pediatric versus adult drug trials for conditions with high pediatric disease burden. Pediatrics. 2012;130(2):285–92. doi:10.1542/peds.2012-0139.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Cuzzolin L, Atzei A, Fanos V. Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Expert Opin Drug Saf. 2006;5(5):703–18.CrossRefPubMedGoogle Scholar
  3. 3.
    Evidence of harm from off-label or unlicensed medicines in children. London: European Medicines Agency; 2004. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2009/10/WC500004021.pdf. Accessed 16 Mar 2017.
  4. 4.
    Saiyed MM, Lalwani T, Rana D. Is off-label use a risk factor for adverse drug reactions in pediatric patients? A prospective study in an Indian tertiary care hospital. Int J Risk Saf Med. 2015;27(1):45–53. doi:10.3233/JRS-150642.PubMedGoogle Scholar
  5. 5.
    Eguale T, Buckeridge DL, Verma A, Winslade NE, Benedetti A, Hanley JA, Tamblyn R. Association of off-label drug use and adverse drug events in an adult population. JAMA Intern Med. 2016;176(1):55–63. doi:10.1001/jamainternmed.2015.6058.CrossRefPubMedGoogle Scholar
  6. 6.
    European Commission. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal medicines for pediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. http://ec.europa.eu/health/files/eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdf. Accessed 16 Mar 2017.
  7. 7.
    Penkov D, Tomasi P, Eichler I, Murphy D, Yao LP, Temeck J. Pediatric medicine development: an overview and comparison of regulatory processes in the European Union and United States. Ther Innov Regul Sci. 2017;51(3):360–71. doi:10.1177/2168479017696265.CrossRefPubMedGoogle Scholar
  8. 8.
  9. 9.
  10. 10.
    Annex—10-year Report to the European Commission. 2016. https://ec.europa.eu/health/sites/health/files/files/paediatrics/2016_pc_report_2017/ema_10_year_report_annex.pdfAccessed 17 Mar 2017.
  11. 11.
    Papaluca M, Greco M, Tognana E, Ehmann F, Saint-Raymond A. White spots in pharmaceutical pipelines-EMA identifies potential areas of unmet medical needs. Expert Rev Clin Pharmacol. 2015;8(3):353–60. doi:10.1586/17512433.2015.1028918.CrossRefPubMedGoogle Scholar
  12. 12.
    Ruperto N, Vesely R, Saint-Raymond A, Martini A, Pediatric Rheumatology International Trials Organisation (PRINTO). Impact of the European pediatric legislation in pediatric rheumatology: past, present and future. Ann Rheum Dis. 2013;72(12):1893–6. doi:10.1136/annrheumdis-2013-204168.CrossRefPubMedGoogle Scholar
  13. 13.
    Saint-Raymond A, Pelle B, Zaccaria C, Sennwitz M, Branch S. Usage of unpublished pediatric data. Arch Dis Child. 2016;101:81–4. doi:10.1136/archdischild-2015-309519.CrossRefPubMedGoogle Scholar
  14. 14.
    European network of paediatric research at the European Medicines Agency (Enpr-EMA). London: EMA; 2017. http://www.ema.europa.eu/ema/index.jsp?curl=pages/partners_and_networks/general/general_content_000303.jsp&mid=WC0b01ac05801df74a . Accessed 15 July 2017.
  15. 15.
    Ruperto N, Eichler I, Herold R, et al. A European network of pediatric research at the European Medicines Agency (Enpr-EMA). Arch Dis Child. 2012;97:185–8.CrossRefPubMedGoogle Scholar
  16. 16.
    EnprEMA database, 2017. http://enprema.ema.europa.eu/enprema/showall.php. Accessed 16 Mar 2017.
  17. 17.
    Lepola P, et al. Pharmaceutical industry and pediatric clinical trial networks in Europe—how do they communicate? Applied Clinical Trials online. 2016. http://www.appliedclinicaltrialsonline.com/pharmaceutical-industry-and-pediatric-clinical-trial-networks-europe-how-do-they-communicate. Accessed 11 May 2017.
  18. 18.
  19. 19.
    Kelly LE, Davies EH, Saint-Raymond A, Tomasi P, Offringa M. Important issues in the justification of a control treatment in pediatric drug trials. Arch Dis Child. 2016;101(10):962–7. doi:10.1136/archdischild-2016-310644.CrossRefPubMedGoogle Scholar
  20. 20.
    Carleer J, Karres J. Juvenile animal studies and paediatric drug development: a European regulatory perspective. Birth Defects Res B Dev Reprod Toxicol. 2011;92(4):254–60. doi:10.1002/bdrb.20310.PubMedGoogle Scholar
  21. 21.
    The 2017 Commission Report on the Paediatric Regulation. https://ec.europa.eu/health/human-use/paediatric-medicines/developments/2016_pc_report_2017_en. Accessed 11 May 2017.
  22. 22.
    Blake KV, Saint-Raymond A, Zaccaria C, Domergue F, Pelle B, Slattery J. Enhanced pediatric pharmacovigilance at the European medicines agency: a novel query applied to adverse drug reaction reports. Paediatr Drugs. 2016;18:55–63. doi:10.1007/s40272-015-0154-0.CrossRefPubMedGoogle Scholar
  23. 23.
    European Medicines Agency. EU Clinical Trials Register. https://www.clinicaltrialsregister.eu/ctr-search/search. Accessed 23 Aug 2017.
  24. 24.
    10-year Report to the European Commission—General report on the experience acquired as a result of the application of the Paediatric Regulation. London: European Medicines Agency; 2016. https://ec.europa.eu/health/sites/health/files/files/paediatrics/2016_pc_report_2017/ema_10_year_report_for_consultation.pdf. Accessed 10 June 2017.
  25. 25.
    Zoely - Summary of Product Characteristics / EPAR. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001213/WC500115831.pdf. Accessed 23 Aug 2017.
  26. 26.
    Results report of Lixisenatide study 2011-004584-67. https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004584-67/results Accessed 23 Aug 2017.
  27. 27.
    The 2017 Commission Report on the Paediatric Regulation. EC 2016: https://ec.europa.eu/health/sites/health/files/files/paediatrics/2016_pc_report_2017/ema_10_year_report_for_consultation.pdf. Accessed 23 Aug 2017.
  28. 28.
    Mentzer D, Desfontaine E, Tomasi PA. The importance and challenge of pediatric trials of hemophilia drugs. Nat Med. 2014;20:465. doi:10.1038/nm.3546.CrossRefPubMedGoogle Scholar
  29. 29.
    European Parliament resolution of 15 December 2016 on the regulation on pediatric medicines. 2016. http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P8-TA-2016-0511. Accessed 17 Mar 2017.
  30. 30.
    AAP makes recommendations on use of off-label drugs for children. Press release; 24 February 2014. https://www.aap.org/en-us/about-the-aap/aap-press-room/pages/AAP-Makes-Recommendations-On-Use-of-Off-Label-Drugs-for-Children.aspx. Accessed 4 May 2017.

Copyright information

© European Union 2017

Authors and Affiliations

  1. 1.European Medicines AgencyLondonUK

Personalised recommendations